Abbott Laboratories (NYSE:ABT) stock fell 0.71% (As on January 23, 11:27:47 AM UTC-4, Source: Google Finance) after the company’s projection of first quarter earnings beneath Wall Street forecasts and its failure to meet revenue targets for the fourth quarter. Nutrition-based revenues reached $1.9 billion, falling significantly below the average analyst target of $2.19 billion. The company’s pediatric division has struggled lately because of competitive rivalry stemming from the loss of a key US government procurement deal last year, coupled with rising production expenses for consumer retail items. Abbott CEO Robert Ford stated that elevated production overhead triggered price hikes, which subsequently dampened consumer demand as buyers grow more conscious of costs. Medical equipment sales, Abbott’s primary business segment, reached $5.67 billion during the fourth quarter, meeting market expectations. Abbott’s testing division has declined post-pandemic as the requirement for Covid kits diminishes.
Moreover, in November, the firm agreed to purchase cancer-detection specialist Exact Sciences Corp. in a transaction valued at roughly $21 billion in total equity. The merger is anticipated to strengthen Abbott’s screening business by providing entry to diagnostics like Cologuard, which aids in detecting colorectal cancer — the second-highest cause of oncological fatalities in the US.
ABT in the fourth quarter of FY25 has reported the adjusted earnings per share of $1.50, which matches the analysts’ estimates for the adjusted earnings per share of $1.50. The company had reported the adjusted revenue growth of 3.8 percent to $11.5 billion in the fourth quarter of FY25, missing the analysts’ estimates for revenue of $11.8 billion. The adjusted gross margin profile was 57.1% of sales, which, despite the impact of tariffs, increased 20 basis points compared to the prior year. Adjusted R&D was 6.2% of sales, and adjusted SG&A was 25.1% of sales. Adjusted operating margin was 25.8% of sales, which reflects an increase of 150 basis points compared to the prior year.
The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing the consensus Wall Street projection of $1.19 per share. Furthermore, Abbott said it expects adjusted profits in the neighborhood of $5.55 to $5.80 for the current year. For 2026, Abbott projects organic sales growth between 6.5% and 7.5%. The company plans to launch several new products, including biosimilars and nutrition products, and aims to expand into the cancer diagnostics market through a planned acquisition of Exact Sciences.